Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2017-02-28 Earnings Release
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Fourth quarter and preliminary 2016 results
Earnings Release Classification · 95% confidence The document is titled "PCI Biotech: Fourth quarter and preliminary 2016 results" and explicitly states, "Please find enclosed the financial report and presentation for fourth quarter and preliminary full year 2016." It provides key highlights, CEO commentary, and details for an upcoming presentation/audiocast regarding these results. Since the document itself is an announcement summarizing results and pointing to the enclosed/attached report (and the total length is relatively short at 4648 characters), it fits the definition of an Earnings Release (ER) which provides initial financial highlights, or potentially a Report Publication Announcement (RPA) because it announces the release of the full report/presentation. Given the content is focused on the *results* (Q4 and preliminary full year), ER is a strong fit. However, the text explicitly mentions the release of the financial report and presentation, and the structure is typical of an announcement preceding the full filing. Since it contains preliminary results and highlights, it aligns best with the Earnings Release (ER) category, which is the initial announcement of periodical financial results (key highlights only). If it were the full, detailed report, it would be an IR (Interim Report) or 10-K, but this is clearly the announcement of those results. Q4 2016
2017-02-28 English
PCI Biotech: Invitation to fourth quarter 2016 presentation
Report Publication Announcement Classification · 98% confidence The document is titled "PCI Biotech: Invitation to fourth quarter 2016 presentation" and explicitly invites recipients to a presentation of the company's fourth quarter 2016 report scheduled for February 28, 2017. It provides details on the time, venue, and how to follow the audiocast. Crucially, it states that the interim report and the presentation will be available from 08 am CET on February 28, 2017. Since this document is an announcement about the upcoming release and presentation of a report (the Q4 2016 report), and not the report itself, it fits the definition of a Report Publication Announcement (RPA). The document length is short (1536 chars), supporting the 'MENU VS MEAL' rule.
2017-02-20 English
PCI Biotech awarded NOK 13.8 million from The Research Council of Norway to further development of PCI for use in vaccination
Regulatory Filings Classification · 100% confidence The document announces that PCI Biotech has been awarded a NOK 13.8 million grant from The Research Council of Norway for project development. This is a specific announcement regarding funding and project development, not a comprehensive annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS). It details financing/capital activity related to R&D, which aligns best with the 'Capital/Financing Update' category, as it concerns securing funds for operations and development. It is not a dividend announcement (DIV), a director's dealing (DIRS), or a management change (MANG). Given the context of receiving a significant grant to fund future development, CAP (Capital/Financing Update) is the most appropriate classification.
2017-01-27 English
PCI Biotech: Capital increase registered and listing of new shares
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces the completion of a 'Capital increase registered and listing of new shares' following a 'fully underwritten rights issue'. This directly relates to changes in the company's capital structure and fundraising activities. The content details the registration of the share capital increase and the resulting new share count. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV).
2017-01-19 English
PCI Biotech: Final results of the rights issue
Share Issue/Capital Change Classification · 99% confidence The document explicitly discusses the 'Final results of the rights issue' for PCI Biotech Holding ASA. It details the subscription period, oversubscription figures, final allocation of shares, expected payment dates, and the resulting impact on the share capital and gross proceeds (NOK 70 million). A rights issue is a specific type of corporate action related to raising capital or changing the capital structure. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a general earnings release (ER), an annual report (10-K), or a simple dividend notice (DIV).
2017-01-10 English
The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway
Capital/Financing Update Classification · 95% confidence The document announces a grant award (NOK 500,000) from Innovation Norway to two companies, PCI Biotech and Ultimovacs, to support their ongoing preclinical research collaboration. This is a specific corporate announcement regarding funding/financing activities, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a formal regulatory filing like a director's dealing or major shareholding notice. The most appropriate category is Capital/Financing Update (CAP), as it details the receipt of grant funding which impacts capital resources and future development plans.
2017-01-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.